News
Public · Published
Ardent Health, Inc. (ARDT) Raises 2026 Adjusted EBITDA Guidance to $500–535M
Ardent Health raised its 2026 adjusted EBITDA guidance to $500–535M from $485–535M, lifting the low end while keeping the high end unchanged. It maintained revenue guidance at $6,400–6,700M, and its board authorized a $25M increase to the share repurchase program.
Published:
Updated:
What happened
Ardent Health raised its 2026 adjusted EBITDA guidance to $500–535M from $485–535M, lifting the low end while keeping the high end unchanged. It maintained revenue guidance at $6,400–6,700M, and its board authorized a $25M increase to the share repurchase program.
Confirmed
Global impact / market context
A higher minimum profit outlook suggests Ardent expects its operating results to be stronger than previously anticipated at the lower end. The unchanged revenue range indicates no corresponding sales forecast increase. The larger buyback authorization gives the company more capacity to repurchase shares, but does not establish that purchases will occur.
Analyst inference
The update accompanies third-quarter results, but the supplied article gives no quarterly financial figures, so investors cannot compare actual performance with expectations here. About $48M remained under the repurchase program as of September 30, 2026; the increased authorization adds capacity, not proof of further spending.
Confirmed
What to watch
- Check future company updates for whether 2026 adjusted EBITDA guidance changes again and whether reported operating results support the raised lower end of the range. Analyst inference
- Compare reported revenue with the maintained outlook; actual sales could clarify whether stronger expected profit comes with revenue growth or other changes. Analyst inference
- Watch for company disclosures on share repurchases and remaining authorization, since the board approved a $25M increase but the article does not say how much will be used. Analyst inference
Evidence
- Original source link unavailable